MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$9,054K
EPS
-$0.03
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Amortization of intangible asset
-0 0 0
Total revenues
53,544 57,622 58,766 62,472
Cost of product and other revenue
12,290 12,535 9,383 9,919
Restructuring
-0 0 0
Total cost of goods sold
12,290 12,535 9,383 9,919
Research and development
14,807 26,648 14,944 11,013
Selling, general and administrative
30,436 26,089 29,094 26,555
License
707 903 896 896
Total operating expenses
45,950 53,640 44,934 38,464
Income (gain) from operations
-4,696 -8,553 4,449 14,089
Interest expense
-4,691 -4,827 -4,748 -6,834
Loss on extinguishment of debt
-0* 0 0
Other income
3 -117 -10 -28
Loss on termination of lease
-0* --
Change in fair value of warrant liability
-456 -2,262 -1,464 6,980
Income (loss) before income taxes
-8,928 -11,235 1,155 247
Income tax expense
126 1,009 615 -
Net income (loss)
-9,054 -12,244 540 247
Comprehensive income (loss)
-9,054 -12,244 540 247
Basic EPS
-0.03 -0.046 0 0
Diluted EPS
-0.03 -0.051 0 0
Basic Average Shares
267,046,755 265,781,476 264,786,432 262,565,500
Diluted Average Shares
267,046,755 241,551,533 274,372,722 271,104,020
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive income (loss)-$9,054K (-248.13%↓ Y/Y)Net income (loss)-$9,054K (-248.13%↓ Y/Y)Auryxia$36,190K Vafseo$15,802K Japan TobaccoIncorporation And Torii...$1,179K Tanabe PharmaCorporation$341K MEDICEArzneimittel Putter Gmb HCo KG$32K Income (loss) beforeincome taxes-$8,928K (-246.07%↓ Y/Y)Income tax expense$126K Change in fair value ofwarrant liability-$456K (-194.19%↓ Y/Y)Other income$3K (-98.59%↓ Y/Y)Product$51,992K License CollaborationAnd Other Revenue$1,552K Income (gain) fromoperations-$4,696K (-134.75%↓ Y/Y)Interest expense-$4,691K (39.63%↑ Y/Y)Total revenues$53,544K (-6.61%↓ Y/Y)Total operatingexpenses$45,950K (26.94%↑ Y/Y)Total cost of goodssold$12,290K (61.18%↑ Y/Y)Selling, general andadministrative$30,436K (18.23%↑ Y/Y)Research and development$14,807K (51.80%↑ Y/Y)License$707K (0.86%↑ Y/Y)Cost of product andother revenue$12,290K (61.18%↑ Y/Y)

Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. (AKBA)